Moderate Crohn's disease

Also known as: Moderate Crohn’s Disease

Drug	Drug Name	Drug Description
DB01222	Budesonide	A corticosteroid used to treat Crohn's disease, asthma, COPD, hay fever and allergies, and ulcerative colitis.
DB08904	Certolizumab pegol	A tumor necrosis factor (TNF) blocker used to treat a variety of autoimmune and autoinflammatory conditions like Crohn's disease, rheumatoid arthritis, active psoriatic arthritis, ankylosing spondylitis, axial spondyloarthritis, and plaque psoriasis.
DB00108	Natalizumab	A monoclonal anti-integrin antibody used to treat Crohn's disease or multiple sclerosis.

Drug	Drug Name	Target	Type
DB01222	Budesonide	Glucocorticoid receptor	target
DB01222	Budesonide	Cytochrome P450 3A4	enzyme
DB01222	Budesonide	Cytochrome P450 3A5	enzyme
DB01222	Budesonide	Bile salt export pump	transporter
DB01222	Budesonide	P-glycoprotein 1	transporter
DB01222	Budesonide	Annexin A1	target
DB01222	Budesonide	Cytochrome P450 3A Subfamily	enzyme
DB01222	Budesonide	Cytochrome P450 2A6	enzyme
DB01222	Budesonide	Cytochrome P450 1B1	enzyme
DB01222	Budesonide	Cytochrome P450 2B6	enzyme
DB01222	Budesonide	Cytochrome P450 2C8	enzyme
DB01222	Budesonide	Cytochrome P450 2C9	enzyme
DB01222	Budesonide	Cytochrome P450 2C19	enzyme
DB01222	Budesonide	Corticosteroid-binding globulin	carrier
DB01222	Budesonide	Solute carrier organic anion transporter family member 1A2	transporter
DB01222	Budesonide	Solute carrier family 22 member 8	transporter
DB01222	Budesonide	Serum albumin	carrier
DB08904	Certolizumab pegol	Tumor necrosis factor	target
DB08904	Certolizumab pegol	Alcohol dehydrogenase [NADP(+)]	enzyme
DB00108	Natalizumab	Integrin alpha-4	target
DB00108	Natalizumab	Low affinity immunoglobulin gamma Fc region receptor III-B	target
DB00108	Natalizumab	High affinity immunoglobulin gamma Fc receptor I	target
DB00108	Natalizumab	Intercellular adhesion molecule 1	target

Drug	Drug Name	Phase	Status	Count